Loading…

Loading grant details…

Active NON-SBIR/STTR RPGS NIH (US)

Interplay of natural killer cells and extracellular matrix proteins in solid cancers

$6.61M USD

Funder NATIONAL CANCER INSTITUTE
Recipient Organization Massachusetts General Hospital
Country United States
Start Date Apr 01, 2024
End Date Mar 31, 2029
Duration 1,825 days
Number of Grantees 1
Roles Principal Investigator
Data Source NIH (US)
Grant ID 10879349
Grant Description

Project Summary/Abstract: Natural killer (NK) cells have long been known to provide critical early defense against viral infections and malignancies. Nevertheless, most of the clinical success associated with using NK cells has been restricted to hematological malignancies, which can be partly attributed to the defective NK cell activation in peripheral

tissues. Extracellular matrix (ECM) proteins are present in all peripheral tissues where they maintain homeostasis by providing scaffold as well as important developmental cues to the surrounding cells. We have recently discovered a critical role for ECM proteins in switching the function of conventional NK cells as they exit

the circulation and enter the peripheral tissues. We aim to investigate how ECM proteins regulate NK cell functions in the skin and solid cancers. Skin and breast cancer are the leading cause of cancer morbidity and mortality in the United States. These cancers frequently develop primary and secondary resistance to current

immunotherapeutics. In addition, chemotherapies for them cause wide-ranging side effects and thus significantly burden the health care system. Defective ECM turnover is a hallmark of skin, breast, and other solid cancers. To fully elucidate the bi-directional interactions between NK cells and ECM in the context of solid cancer

development, we aim to (1) Determine the mechanism of collagen-induced loss of NK cell killing function in solid cancers, (2) Determine the role of collagen-III in the regulation of NK cell helper function in solid cancers, and (3) Examine the impact of other major ECM proteins on NK cell functionality. The outcomes of the proposed

studies will reveal novel mechanisms of ECM-NK cell interactions in cancer. Our research will greatly facilitate the development of novel therapeutic strategies to harness NK cells for the treatment of solid cancers.

All Grantees

Massachusetts General Hospital

Advertisement
Discover thousands of grant opportunities
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant